Pablo Martín-Gago

Hit Discovery

Pablo is currently a Principal Scientist and the head of the Hit Discovery team at LEO Pharma, where he leads chemical biology and medicinal chemistry efforts to identify, validate and develop novel molecules for treating skin diseases. Pablo Martín-Gago completed his Ph.D. at the IRB Barcelona with Prof. A. Riera. After a research stay in the Fu Lab at Caltech, he joined the Max Planck Institute as a postdoc with Prof. H. Waldmann to develop inhibitors of the KRas-PDEδ interaction. After joining Copenhagen University as an assistant professor designing covalent probes for epigenetic targets, he moved to Lundbeck, where he worked on multiple hit-finding campaigns and early-stage drug discovery projects targeting CNS disorders. 
More from Pablo

Methods for Identifying Ligand Binding Sites in Drug Discovery

Understanding how a small molecule ligand binds to its target is valuable in drug discovery, because it enables more efficient optimization through structure-based design, better mechanistic understanding of molecular pharmacology, and greater confidence in the therapeutic hypothesis from both safety and efficacy perspectives. Recently, Drug Hunter highlighted methods for target identification when the target is unknown.

Resource

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.